Trial intelligence / Profile preview

Trifluridine/tipiracil ± bevacizumab with or without XB2001 in metastatic colorectal cancer

2024-517024-20-00Phase 2Authorised

Sponsor: Centre Georges-François Leclerc
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in metastatic colon cancer (mCRC) comparing XB2001 arm with Placebo arm (2 arms). Planned start Nov 2024; status: authorised.

Drugs

XB2001

Conditions

metastatic colon cancer (mCRC)

Beyond the preview

Go deeper on 2024-517024-20-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-517024-20-00.